"Lisinopril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
| Descriptor ID |
D017706
|
| MeSH Number(s) |
D12.644.456.345.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lisinopril".
Below are MeSH descriptors whose meaning is more specific than "Lisinopril".
This graph shows the total number of publications written about "Lisinopril" by people in this website by year, and whether "Lisinopril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lisinopril" by people in Profiles.
-
Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 03 01; 103(3):686-696.
-
Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J. 2016 Jan; 30(1):370-9.
-
Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 2015 Nov; 29(11):4544-54.
-
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov; 29(11):1475-83.
-
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008 Oct; 10(10):751-60.
-
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008 Jan 28; 168(2):207-17.
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
-
Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation. 2003 Feb 04; 107(4):586-92.
-
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001 Apr; 24(4):654-8.
-
Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by blood pressure reduction alone. J Hypertens. 1993 Oct; 11(10):1113-20.